The portfolio maintains a sizable cost advantage over competitors, priced within the cheapest fee quintile among peers.
iShares Biotechnology ETF IBB
- NAV / 1-Day Return 142.67 / +1.13 %
- Total Assets 7.5 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.450%
- Distribution Fee Level —
- Share Class Type —
- Category Health
- Investment Style Mid Growth
- Min. Initial Investment —
- Status Open
- TTM Yield 0.27%
- Turnover 22%
USD | NAV as of Sep 26, 2024 | 1-Day Return as of Sep 26, 2024, 11:13 PM GMT+0
Morningstar’s Analysis IBB
Will IBB outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 49.7
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Gilead Sciences Inc | 8.66 | 658.7 Mil | Healthcare |
Amgen Inc | 8.09 | 615.6 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 7.62 | 579.8 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 7.21 | 548.3 Mil | Healthcare |
IQVIA Holdings Inc | 4.20 | 319.5 Mil | Healthcare |
Alnylam Pharmaceuticals Inc | 3.34 | 254.3 Mil | Healthcare |
Mettler-Toledo International Inc | 2.94 | 223.8 Mil | Healthcare |
Biogen Inc | 2.72 | 206.9 Mil | Healthcare |
argenx SE ADR | 2.56 | 194.7 Mil | Healthcare |
BioNTech SE ADR | 2.33 | 177.0 Mil | Healthcare |